Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > Press > Nanophase Reports First Quarter 2009 Financial Results: Nanophase Continues to Execute New Strategy

Abstract:
Nanophase Technologies Corporation (Nasdaq: NANX), a technology leader in nanomaterials and advanced nanoengineered products, reported today financial results for its first quarter ending March 31, 2009.

Nanophase Reports First Quarter 2009 Financial Results: Nanophase Continues to Execute New Strategy

ROMEOVILLE, IL | Posted on May 8th, 2009

First Quarter

Revenue for first quarter 2009 was $1.4 million, compared to $3.0 million for the same period in 2008. The net loss for the quarter was $2.1 million, or $0.10 per share, compared to a net loss of $0.8 million, or $0.04 per share, for the first quarter of 2008. Of the $2.1 million loss in Q1 of 2009, 37% was due to severance charges related to the Company's February 2009 reorganization.

Looking Ahead

"We remain focused on building our pipeline by leveraging our technology platform and applications development know-how," said Jess Jankowski, Nanophase president and CEO. "Our new way of going to market, with a major emphasis on our internal sales and application development team to drive new business, will make Nanophase fundamentally different and should lead to greater success. To that end, we have refocused our research and development efforts so that they are aligned with the market driven, direct-to-the-customer model. In addition to continuing to serve the needs of our existing partners, we are intent on building applications expertise in carefully selected market segments that we thoroughly understand, talking to customers and potential customers, tailoring our product offerings towards identified unmet needs where there is a strong value proposition."

"We believe this approach is already resulting in a higher number of quality opportunities and will improve the rate at which we can move those opportunities through the applications development and sales cycles to revenue. We have developed, and continue to develop, ready-to-go products that should serve the customer's needs much more directly. We expect the prospects for success will be improved relative to our previous model."

Shareholders and members of the financial community are encouraged to participate in today's conference call, where Jankowski will be discussing the company's first quarter performance and 2009 prospects.

1st Quarter Conference Call

Nanophase has scheduled its quarterly conference call for May 8, 2009, at 4:00 p.m. CDT (5:00 p.m. EDT), which will be hosted by Jess Jankowski, president and CEO. To participate in the call you may dial 800-344-8034, or 785-830-1990 and reference the conference identification of 7NANOPHASE. The call may also be accessed through the company's website, www.nanophase.com, by clicking on the link under Investor Relations and Calendar of Events. If you are unable to attend, a replay will be available through May 15, 2009, by dialing 800-688-7036, or 402-220-1346, or by logging onto the company's website and following the above directions.

####

About Nanophase Technologies Corporation
Nanophase Technologies Corporation (NANX), www.nanophase.com, is a leader in nanomaterials technologies and provides nanoengineered solutions for multiple industrial product applications. Using a platform of patented and proprietary integrated nanomaterial technologies, the Company creates products with unique performance attributes from two ISO 9001:2000 and ISO 14001 facilities. Nanophase delivers commercial quantity and quality nanoparticles, coated nanoparticles, and nanoparticle dispersions in a variety of media.

Forward-Looking Statements

This press release contains words such as "expects," "shall," "will," , "believes," and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company's current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company's results of operations, performance and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company's dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company's nanocrystalline materials; the Company's manufacturing capacity and product mix flexibility in light of customer demand; the Company's limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company's dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; and other factors described in the Company's Form 10-K filed March 25, 2009. In addition, the Company's forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties or other contingencies.

                       NANOPHASE TECHNOLOGIES CORPORATION

                                 BALANCE SHEETS
                                  (Unaudited)


                                                   March 31,    December 31,
                      ASSETS                        2009            2008
                                                    ----            ----

    Current assets:
      Cash and cash equivalents                   $489,592        $723,069
      Investments                                5,141,210       6,908,888
      Trade accounts receivable, less
       allowance for doubtful accounts
       of $9,000 on March 31, 2009
       and December 31, 2008                       739,488       1,092,125
      Other receivables, net                             -           7,749
      Inventories, net                           1,232,282       1,154,207
      Prepaid expenses and other current
       assets                                      657,526         482,452
                                                   -------         -------
        Total current assets                     8,260,098      10,368,490

      Investments                                5,340,000       5,340,000
      Equipment and leasehold improvements,
       net                                       6,346,761       6,651,842
      Other assets, net                             39,150          39,765
                                                    ------          ------
                                               $19,986,009     $22,400,097
                                               ===========     ===========

             LIABILITIES AND STOCKHOLDERS' EQUITY
    Current liabilities:
      Current portion of capital
       lease obligations                           $12,858         $22,211
      Current portion of long-term debt, less
       unamortized debt discount                 1,052,906       1,570,346
      Current portion of deferred other
       revenue                                      42,426          74,243
      Accounts payable                             355,631         356,853
      Accrued expenses                           1,266,458       1,493,262
      Accrued severance                            708,181         541,014
                                                   -------         -------
        Total current liabilities                3,438,460       4,057,929
                                                 ---------       ---------

      Long-term portion of capital
       lease obligations                             7,174           9,219
      Deferred other revenue,
       less current portion                              -               -
                                                       ---             ---
                                                     7,174           9,219
                                                     -----           -----

    Contingent liabilities:                              -               -

    Stockholders' equity:
      Preferred stock, $.01 par value,
       24,088 shares authorized and
       no shares issued and outstanding                  -               -
      Common stock, $.01 par value, 30,000,000
       shares authorized; 21,204,162
       and 21,188,912 shares issued and
       outstanding on March 31, 2009 and
       December 31, 2008, respectively             212,042         211,889
      Additional paid-in capital                91,913,456      91,597,529
      Accumulated deficit                      (75,585,123)    (73,476,469)
                                               -----------     -----------
        Total stockholders' equity              16,540,375      18,332,949
                                                ----------      ----------
                                               $19,986,009     $22,400,097
                                               ===========     ===========



            NANOPHASE TECHNOLOGIES CORPORATION

                 STATEMENTS OF OPERATIONS

                       (Unaudited)


                                Three months ended
                                     March 31,
                                          As Adjusted
                                 2009         2008
                                 ----         ----
    Revenue:
      Product revenue        $1,296,813   $2,942,722
      Other revenue             108,345      111,386
                                -------      -------
        Total revenue         1,405,158    3,054,108

    Operating expense:
      Cost of revenue         1,314,924    2,000,208
                              ---------    ---------
        Gross Profit             90,234    1,053,900

      Research and
       development expense      404,044      438,695
      Selling, general and
       administrative
       expense                1,000,167    1,574,744
      Severance charges         794,069            -
                                -------          ---
    Loss from operations     (2,108,046)    (959,539)
    Interest income              34,003      167,221
    Interest expense            (20,907)     (38,416)
    Other, net                  (13,704)       2,231
                                -------        -----
    Loss before provision
     for income taxes        (2,108,654)    (828,503)

    Provision for income
     taxes                            -            -
                                    ---          ---
    Net loss                $(2,108,654)   $(828,503)
                            ===========    =========


    Net loss per share-
     basic and diluted           $(0.10)      $(0.04)
                                 ======       ======

    Weighted average number
     of basic and diluted
     common shares
     outstanding             21,197,384   21,106,607
                             ==========   ==========



                      NANOPHASE TECHNOLOGIES CORPORATION

                 STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE

                                  (Unaudited)

                                  Three months ended March 31
                                                 As Adjusted
                                   2009               2008
                                   ----               ----
    Revenue:
      Product revenue, net     $1,296,813         $2,942,722
      Other revenue               108,345            111,386
                                  -------            -------
        Total revenue           1,405,158          3,054,108

    Operating expense:
      Cost of revenue detail:
      Depreciation                259,374            238,044
      Non-Cash equity
       compensation               219,039             16,771
      Other costs of revenue      836,511          1,745,393
                                  -------          ---------
        Cost of revenue         1,314,924          2,000,208
                                ---------          ---------
          Gross profit             90,234          1,053,900

      Research and development
       expense detail:
      Depreciation                 57,043             58,458
      Non-Cash equity
       compensation                22,274             31,032
      Other research and
       development expense        324,727            349,205
                                  -------            -------
        Research and
         development expense      404,044            438,695

      Selling, general and
       administrative expense
       detail:
      Depreciation and
       amortization                20,342             14,551
      Non-Cash equity
       compensation                74,769            152,660
      Trademark abandonment
       charge                           -             37,214
      Other selling, general
       and administrative
       expense                    905,056          1,370,319
                                  -------          ---------
        Selling, general and
         administrative
         expense                1,000,167          1,574,744
        Severance charges         794,069                  -
                                  -------                ---
    Loss from operations       (2,108,046)          (959,539)
    Interest income                34,003            167,221
    Interest expense              (20,907)           (38,416)
    Other, net                    (13,704)             2,231
                                  -------              -----
    Loss before provision
     for income taxes          (2,108,654)          (828,503)
    Provision for income
     taxes                              -                  -
                                      ---                ---
    Net loss                  $(2,108,654)         $(828,503)
                              ===========          =========


For more information, please click here

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

University of Tehran Researchers Invent Non-Enzyme Sensor to Detect Blood Sugar April 23rd, 2014

Gold nanoparticles help target, quantify breast cancer gene segments in a living cell April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Announcements

Characterizing inkjet inks: Malvern Instruments presents new rheological research April 23rd, 2014

NanoSafe, Inc. announces the addition of the Labconco Protector® Glove Box to its NanoSafe Tested™ registry April 23rd, 2014

Study finds long-term survival of human neural stem cells transplanted into primate brain April 23rd, 2014

High-Performance, Low-Cost Ultracapacitors Built with Graphene and Carbon Nanotubes: Future devices based on technology could bridge gap between batteries and conventional capacitors in portable electronics and hybrid electric vehicles April 23rd, 2014

Patents/IP/Tech Transfer/Licensing

Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014

Nanoparticles cause cancer cells to self-destruct April 3rd, 2014

A*STAR's Simtech collaboration agreements to accelerate the growth and development of the microfluidics industry April 1st, 2014

Dolomite releases novel droplet-on-demand sequencing and droplet generation microfluidic system April 1st, 2014

Financial Reports

Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014

Acid folic was used in the production of the nanogel as targeting agent in drug delivery. The nanogel can be used in the treatment of cancer as a stable nanocarrier. Stability of nanocarriers is an important issue in target delivery mechanisms. Most of nanocarriers, due to their March 17th, 2014

Arrowhead Reports Fiscal 2014 First Quarter Financial Results - Conference Call Today at 4:30 p.m. Eastern Time February 4th, 2014

Arrowhead to Report Fiscal 2014 First Quarter Financial Results - Conference Call Scheduled for Tuesday, February 4, 2014 January 28th, 2014

Industrial

Vacuum Ultraviolet Lamp of the Future Created in Japan: First Solid-State Vacuum UV Phosphor, Described in APL-Materials, Promises Smaller, Safer, Longer Lasting, Low Power Lamps for Industrial Applications April 22nd, 2014

Shiny quantum dots brighten future of solar cells: Photovoltaic solar-panel windows could be next for your house April 14th, 2014

Industrial Nanotech, Inc. Lands First Major Order from Pemex, Mexico’s State-Owned Oil and Gas Company April 14th, 2014

Industrial Nanotech, Inc. Announces Certification for Use in Middle East for Buildings: Nansulate(R) Energy Saving Coatings to be used by Major Middle East Energy Company April 1st, 2014

Events/Classes

Characterizing inkjet inks: Malvern Instruments presents new rheological research April 23rd, 2014

PETA science consortium to present hazard testing strategy at nanotoxicology meeting: High tech field ripe for use of sophisticated non-animal testing strategies April 22nd, 2014

National Space Society Congratulates SpaceX on the Success of CRS-3 and the First Flight of the Falcon 9R April 22nd, 2014

INSCX™ exchange to present Exchange trade reporting mechanism for engineered nanomaterials (NMs) to UK regulation agencies, insurers and upstream/downstream users April 17th, 2014

NanoNews-Digest
The latest news from around the world, FREE







  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More














ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE